Eton Pharmaceuticals, Inc.

ETON · Nasdaq · United States

Share price · ETON

$61.99-1.44 (-2.27%) 3M

close as of 2026-11-18 · 24h delayed · vol 489K (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ETON's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026+19.7%
  2. 30 Sep 2026-13.0%

    Nothing announced by ETON that day or the session before.

  3. 14 Aug 2026+44.3%
  4. 28 Jul 2026+10.3%

    Nothing announced by ETON that day or the session before.

  5. 17 Jul 2026+13.8%
  6. 18 May 2026+7.4%

    Nothing announced by ETON that day or the session before.

  7. 1 May 2026+19.8%

    Nothing announced by ETON that day or the session before.

  8. 16 Apr 2026-9.4%

    Nothing announced by ETON that day or the session before.

  9. 20 Mar 2026+7.5%

    Nothing announced by ETON that day or the session before.

  10. 19 Mar 2026+9.2%

    Nothing announced by ETON that day or the session before.

Share of unusual movement by asset

For each asset, the share of ETON's own-move activity since 27 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Diazepam (Libervant) (Libervant)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—42%
Sessions with no dated event—58%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
GABA-A receptorSmall molecule
Epilepsy

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

29 March 2027FDA action dateLibervant (diazepam) buccal filmPDUFA date for the Libervant Type 9 NDA (ages 6 to 11)
US, FDA · Aquestive Therapeutics, Inc. (US licensee Eton Pharmaceuticals from 2026-10-14) · Source ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$58M$5.3M$56M—$35M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$38M$1.0M$27M—$7.3M operating cash flowreport ↗
2026-Q1$24M$1.9M$20M—$7.4M operating cash flowreport ↗
2025-Q3$22M$1.1M$37M$1.9M$12M operating cash flowreport ↗
2025-Q2$19M$3.7M$25M$2.6M$8.0M operating cash flowreport ↗
2025-Q1$17M$1.2M$17M$1.6M$2.1M operating cash flowreport ↗
2024-Q3$10M$0.5M$20M—$3.0M operating cash flowreport ↗
2024-Q2$9.1M$3.0M$18M$3.0M$1.3M operating cash flowreport ↗
2024-Q1$8.0M$0.7M$17M$0.8M-$2.5M operating cash flowreport ↗
2023-Q3$7.0M$0.6M$22M$0.6M$0.9M operating cash flowreport ↗
2023-Q2$12M$1.1M$22M—$7.1M operating cash flowreport ↗
2023-Q1$5.3M$0.5M$15M$2.7M-$1.6M operating cash flowreport ↗
2022-Q3$3.2M$0.7M$13M$3.0M-$1.7M operating cash flowreport ↗
2022-Q2$7.4M$0.7M$17M$1.6M$2.5M operating cash flowreport ↗
2022-Q1$2.2M$1.6M$15M$5.3M$1.2M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$80M$7.8M$26M$1.1M$11M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$39M$3.3M$15M$1.0M$1.0M operating cash flowreport ↗
2023-FY$32M$3.3M$21M$0.2M$6.8M operating cash flowreport ↗
2022-FY$21M$4.0M$16M$2.3M$4.8M operating cash flowreport ↗
2021-FY$22M$6.2M$14M$0.5M-$4.7M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 36 sales ($35.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-10Erdogan-Trinkaus Ipek · Chief Commercial OfficerOption exercise3,500$15.47$54KForm 4
2026-11-10Erdogan-Trinkaus Ipek · Chief Commercial OfficerOpen-market sale2,340$67.18$157KForm 4
2026-11-10Erdogan-Trinkaus Ipek · Chief Commercial OfficerOpen-market sale1,160$67.88$79KForm 4
2026-11-10Erdogan-Trinkaus Ipek · Chief Commercial OfficerOption exercise (derivative)3,500——Form 4
2026-11-10CASAMENTO CHARLES J · directorOption exercise12,500$7.31$91KForm 4
2026-11-10CASAMENTO CHARLES J · directorOption exercise27,400$3.58$98KForm 4
2026-11-10CASAMENTO CHARLES J · directorOption exercise19,655$8.61$169KForm 4
2026-11-10CASAMENTO CHARLES J · directorOption exercise21,000$3.78$79KForm 4